Interpace Diagnostics Group Inc (NASDAQ:IDXG) has been given an average recommendation of “Buy” by the seven brokerages that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $3.55.
Several research firms recently weighed in on IDXG. Maxim Group reissued a “buy” rating and set a $4.00 price objective on shares of Interpace Diagnostics Group in a report on Monday, September 24th. HC Wainwright set a $3.00 price objective on Interpace Diagnostics Group and gave the company a “buy” rating in a report on Friday, October 5th. Dawson James began coverage on Interpace Diagnostics Group in a report on Wednesday, October 17th. They set a “buy” rating and a $4.00 price objective on the stock. Finally, Zacks Investment Research downgraded Interpace Diagnostics Group from a “buy” rating to a “hold” rating in a report on Saturday, November 17th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. acquired a new stake in shares of Interpace Diagnostics Group during the 3rd quarter valued at $194,000. Virtu Financial LLC acquired a new stake in shares of Interpace Diagnostics Group during the 3rd quarter valued at $172,000. Essex Investment Management Co. LLC acquired a new stake in shares of Interpace Diagnostics Group during the 3rd quarter valued at $465,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of Interpace Diagnostics Group during the 3rd quarter valued at $983,000. 16.63% of the stock is currently owned by institutional investors.
Interpace Diagnostics Group (NASDAQ:IDXG) last issued its quarterly earnings results on Tuesday, November 13th. The business services provider reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.04). Interpace Diagnostics Group had a negative net margin of 64.40% and a negative return on equity of 33.67%. The business had revenue of $5.75 million during the quarter, compared to the consensus estimate of $5.50 million. Analysts anticipate that Interpace Diagnostics Group will post -0.36 EPS for the current year.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Featured Story: Understanding the different types of bonds
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.